Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Lipid Luminations

Lipid Lowering: The End or the Means to Better CV Results?

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    The answer almost assuredly is patient-specific, but the question of lipid-lowering as the end or the means in measuring cardiovascular risk highlights the ongoing discussion in medicine about targets: whether how we get there is more important than just getting there. Dr. Roger Blumenthal, professor of medicine in the division of cardiology at Johns Hopkins University School of Medicine, goes beyond a focus on lipid numbers in this discussion with host Dr. Larry Kaskel. As Dr. Blumenthal explains, cost-effectiveness is a critical consideration when examining target points in lipid therapy.

     

    Brought to you by:

    NLA logo

     

Recommended
Details
Presenters
Comments
  • Overview

    The answer almost assuredly is patient-specific, but the question of lipid-lowering as the end or the means in measuring cardiovascular risk highlights the ongoing discussion in medicine about targets: whether how we get there is more important than just getting there. Dr. Roger Blumenthal, professor of medicine in the division of cardiology at Johns Hopkins University School of Medicine, goes beyond a focus on lipid numbers in this discussion with host Dr. Larry Kaskel. As Dr. Blumenthal explains, cost-effectiveness is a critical consideration when examining target points in lipid therapy.

     

    Brought to you by:

    NLA logo

     

Schedule12 Nov 2024